Hydrochloric Acid → Erlotinib hydrochloride

HRID 243532

反応式

HRID 243532 の反応式
[CH3:1][O:2][CH2:3][CH2:4][O:5][C:6]1[CH:11]=[C:10]2[C:12]([NH:16][C:17]3[CH:22]=[C:21]([C:23]#[CH:24])[CH:20]=[CH:19][CH:18]=3)=[N:13][CH:14]=[N:15][C:9]2=[CH:8][C:7]=1[O:25][CH2:26][CH2:27][O:28][CH3:29].O1CCOCC1.[ClH:36]>C(O)(C)C>[CH3:1][O:2][CH2:3][CH2:4][O:5][C:6]1[CH:11]=[C:10]2[C:12]([NH:16][C:17]3[CH:18]=[CH:19][CH:20]=[C:21]([C:23]#[CH:24])[CH:22]=3)=[N:13][CH:14]=[N:15][C:9]2=[CH:8][C:7]=1[O:25][CH2:26][CH2:27][O:28][CH3:29].[ClH:36]

参加物

5

実験手順

10.0 g crystal form IV of erlotinib base was added to 200 ml 1,4-dioxane, heated to dissolve until being clarified, 6.4 g isopropanol saturated with HCl gas was added dropwise at 60-70° C., after dripping, stirred for 30 minutes while maintaining the temperature, stirred for 1 hour at 0-15° C. before filtration, dried at 50° C. to obtain 10.6 g sample of crystal form A. The yield was 97.2% and the purity was 99.8% (by HPLC).

後処理

  1. temperatureheated
  2. dissolutionto dissolve
  3. temperaturewhile maintaining the temperature
  4. stirringstirred for 1 hour at 0-15° C. before filtration
  5. customdried at 50° C.
  6. customto obtain 10.6 g sample of crystal form A

出典と根拠

ORDレコード
ord-6190bf32fedb433b972574d6bf7167e2
出典データセット
uspto-grants-2014_02
特許番号
US08653264B2

関連ノート

読み込み中…